Table 1.
Toxicity associated with photon and proton therapy for Optic Pathway/Hypothalamic Glioma.
| Study | Modality | Patients (n) | Median follow up (years) | 5y OS/LC | Hearing loss | Endocrine deficiency | Growth HormoneDeficiency | Secondary tumor | Vasculopathy | Radionecrosis |
|---|---|---|---|---|---|---|---|---|---|---|
| Williams, 2018 (10) | Photons | 29 | 17.8 | 89%/82% | 1% | 26% | 22% | 13% | 4% | |
| Armstrong, 2011 (20) | Photons | 361 | 15 | 3.3%*** | 60% | |||||
| Fouladi, 2003 (24) | Photons | 73 | 6.3 | 69%/68%** | 85% | 60% | ||||
| Merchant, 2009 (22) | Photons | 78 | 7.4 | 12% | 46% 5-yr, 49% 10-yr | |||||
| Tsang, 2017 (25) | Photons* | 89 | 12.5 | 9% | ||||||
| Tao, 1997 (26) | Photons | 29 | 6.2 | 100%/95% | 72% | 59% | ||||
| Brauner, 1990 (27) | Photons | 21 | 100% | 100% | ||||||
| Collet-Solberg, 1997 (28) | Photons | 38 | 5.6 | 39% | ||||||
| Indelicato, 2019 (12) | Protons | 174 | 4.4 | 93%/89% | 2% | 22% | 18% | 1% | 1% | |
| Greenberger, 1997 (29) | Protons | 32 | 7.6 | 100%/90% | ~75% | 6% | ||||
| Hug, 2014 (30) | Protons | 15 | 3.3 | 93%/87% | 27% |
Toxicity data is included as described in available publications. Missing datapoints are represented by empty cells. *These patients were treated with 95% photon and 5% proton plans due to logistical constraints. **Data is reported as 6-year OS and LC. ***The rate of hearing loss is increased to 20.3% among patients with tumor progression.